NSAID use reduces breast cancer recurrence in overweight and obese women: Role of prostaglandin-aromatase interactions

Laura W. Bowers, Ilane X F Maximo, Andrew Brenner, Muralidhar Beeram, Stephen D. Hursting, Ramona S. Price, Rajeshwar R Tekmal, Christopher A. Jolly, Linda A. DeGraffenried

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Obesity is associated with a worse breast cancer prognosis and elevated levels of inflammation, including greater cyclooxygenase-2 (COX-2) expression and activity in adipose-infiltrating macrophages. The product of this enzyme, the proinflammatory eicosanoid prostaglandin E2 (PGE2), stimulates adipose tissue aromatase expression and subsequent estrogen production, which could promote breast cancer progression. This study demonstrates that daily use of a nonsteroidal anti-inflammatory drug (NSAID), which inhibits COX-2 activity, is associated with reduced estrogen receptor a (ERa)-positive breast cancer recurrence in obese and overweight women. Retrospective review of data from ERa-positive patients with an average body mass index of >30 revealed that NSAID users had a 52% lower recurrence rate and a 28-month delay in time to recurrence. To examine the mechanisms that may be mediating this effect, we conducted in vitro studies that utilized sera from obese and normal-weight patients with breast cancer. Exposure to sera from obese patients stimulated greater macrophage COX-2 expression and PGE2 production. This was correlated with enhanced preadipocyte aromatase expression following incubation in conditioned media (CM) collected from the obese-patient, sera-exposed macrophages, an effect neutralized by COX-2 inhibition with celecoxib. In addition, CM from macrophage/preadipocyte cocultures exposed to sera from obese patients stimulated greater breast cancer cell ERa activity, proliferation, and migration compared with sera from normal-weight patients, and these differences were eliminated or reduced by the addition of an aromatase inhibitor during CM generation. Prospective studies designed to examine the clinical benefit of NSAID use in obese patients with breast cancer are warranted.

Original languageEnglish (US)
Pages (from-to)4446-4457
Number of pages12
JournalCancer Research
Volume74
Issue number16
DOIs
StatePublished - Aug 15 2014

Fingerprint

Aromatase
Prostaglandins
Anti-Inflammatory Agents
Breast Neoplasms
Recurrence
Cyclooxygenase 2
Pharmaceutical Preparations
Conditioned Culture Medium
Macrophages
Estrogen Receptors
Serum
Celecoxib
Dinoprostone
Weights and Measures
Aromatase Inhibitors
Eicosanoids
Coculture Techniques
Drug Users
Adipose Tissue
Estrogens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Bowers, L. W., Maximo, I. X. F., Brenner, A., Beeram, M., Hursting, S. D., Price, R. S., ... DeGraffenried, L. A. (2014). NSAID use reduces breast cancer recurrence in overweight and obese women: Role of prostaglandin-aromatase interactions. Cancer Research, 74(16), 4446-4457. https://doi.org/10.1158/0008-5472.CAN-13-3603

NSAID use reduces breast cancer recurrence in overweight and obese women : Role of prostaglandin-aromatase interactions. / Bowers, Laura W.; Maximo, Ilane X F; Brenner, Andrew; Beeram, Muralidhar; Hursting, Stephen D.; Price, Ramona S.; Tekmal, Rajeshwar R; Jolly, Christopher A.; DeGraffenried, Linda A.

In: Cancer Research, Vol. 74, No. 16, 15.08.2014, p. 4446-4457.

Research output: Contribution to journalArticle

Bowers, LW, Maximo, IXF, Brenner, A, Beeram, M, Hursting, SD, Price, RS, Tekmal, RR, Jolly, CA & DeGraffenried, LA 2014, 'NSAID use reduces breast cancer recurrence in overweight and obese women: Role of prostaglandin-aromatase interactions', Cancer Research, vol. 74, no. 16, pp. 4446-4457. https://doi.org/10.1158/0008-5472.CAN-13-3603
Bowers, Laura W. ; Maximo, Ilane X F ; Brenner, Andrew ; Beeram, Muralidhar ; Hursting, Stephen D. ; Price, Ramona S. ; Tekmal, Rajeshwar R ; Jolly, Christopher A. ; DeGraffenried, Linda A. / NSAID use reduces breast cancer recurrence in overweight and obese women : Role of prostaglandin-aromatase interactions. In: Cancer Research. 2014 ; Vol. 74, No. 16. pp. 4446-4457.
@article{feb3d09cf3ed47b7abb128c5ca185f80,
title = "NSAID use reduces breast cancer recurrence in overweight and obese women: Role of prostaglandin-aromatase interactions",
abstract = "Obesity is associated with a worse breast cancer prognosis and elevated levels of inflammation, including greater cyclooxygenase-2 (COX-2) expression and activity in adipose-infiltrating macrophages. The product of this enzyme, the proinflammatory eicosanoid prostaglandin E2 (PGE2), stimulates adipose tissue aromatase expression and subsequent estrogen production, which could promote breast cancer progression. This study demonstrates that daily use of a nonsteroidal anti-inflammatory drug (NSAID), which inhibits COX-2 activity, is associated with reduced estrogen receptor a (ERa)-positive breast cancer recurrence in obese and overweight women. Retrospective review of data from ERa-positive patients with an average body mass index of >30 revealed that NSAID users had a 52{\%} lower recurrence rate and a 28-month delay in time to recurrence. To examine the mechanisms that may be mediating this effect, we conducted in vitro studies that utilized sera from obese and normal-weight patients with breast cancer. Exposure to sera from obese patients stimulated greater macrophage COX-2 expression and PGE2 production. This was correlated with enhanced preadipocyte aromatase expression following incubation in conditioned media (CM) collected from the obese-patient, sera-exposed macrophages, an effect neutralized by COX-2 inhibition with celecoxib. In addition, CM from macrophage/preadipocyte cocultures exposed to sera from obese patients stimulated greater breast cancer cell ERa activity, proliferation, and migration compared with sera from normal-weight patients, and these differences were eliminated or reduced by the addition of an aromatase inhibitor during CM generation. Prospective studies designed to examine the clinical benefit of NSAID use in obese patients with breast cancer are warranted.",
author = "Bowers, {Laura W.} and Maximo, {Ilane X F} and Andrew Brenner and Muralidhar Beeram and Hursting, {Stephen D.} and Price, {Ramona S.} and Tekmal, {Rajeshwar R} and Jolly, {Christopher A.} and DeGraffenried, {Linda A.}",
year = "2014",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-13-3603",
language = "English (US)",
volume = "74",
pages = "4446--4457",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - NSAID use reduces breast cancer recurrence in overweight and obese women

T2 - Role of prostaglandin-aromatase interactions

AU - Bowers, Laura W.

AU - Maximo, Ilane X F

AU - Brenner, Andrew

AU - Beeram, Muralidhar

AU - Hursting, Stephen D.

AU - Price, Ramona S.

AU - Tekmal, Rajeshwar R

AU - Jolly, Christopher A.

AU - DeGraffenried, Linda A.

PY - 2014/8/15

Y1 - 2014/8/15

N2 - Obesity is associated with a worse breast cancer prognosis and elevated levels of inflammation, including greater cyclooxygenase-2 (COX-2) expression and activity in adipose-infiltrating macrophages. The product of this enzyme, the proinflammatory eicosanoid prostaglandin E2 (PGE2), stimulates adipose tissue aromatase expression and subsequent estrogen production, which could promote breast cancer progression. This study demonstrates that daily use of a nonsteroidal anti-inflammatory drug (NSAID), which inhibits COX-2 activity, is associated with reduced estrogen receptor a (ERa)-positive breast cancer recurrence in obese and overweight women. Retrospective review of data from ERa-positive patients with an average body mass index of >30 revealed that NSAID users had a 52% lower recurrence rate and a 28-month delay in time to recurrence. To examine the mechanisms that may be mediating this effect, we conducted in vitro studies that utilized sera from obese and normal-weight patients with breast cancer. Exposure to sera from obese patients stimulated greater macrophage COX-2 expression and PGE2 production. This was correlated with enhanced preadipocyte aromatase expression following incubation in conditioned media (CM) collected from the obese-patient, sera-exposed macrophages, an effect neutralized by COX-2 inhibition with celecoxib. In addition, CM from macrophage/preadipocyte cocultures exposed to sera from obese patients stimulated greater breast cancer cell ERa activity, proliferation, and migration compared with sera from normal-weight patients, and these differences were eliminated or reduced by the addition of an aromatase inhibitor during CM generation. Prospective studies designed to examine the clinical benefit of NSAID use in obese patients with breast cancer are warranted.

AB - Obesity is associated with a worse breast cancer prognosis and elevated levels of inflammation, including greater cyclooxygenase-2 (COX-2) expression and activity in adipose-infiltrating macrophages. The product of this enzyme, the proinflammatory eicosanoid prostaglandin E2 (PGE2), stimulates adipose tissue aromatase expression and subsequent estrogen production, which could promote breast cancer progression. This study demonstrates that daily use of a nonsteroidal anti-inflammatory drug (NSAID), which inhibits COX-2 activity, is associated with reduced estrogen receptor a (ERa)-positive breast cancer recurrence in obese and overweight women. Retrospective review of data from ERa-positive patients with an average body mass index of >30 revealed that NSAID users had a 52% lower recurrence rate and a 28-month delay in time to recurrence. To examine the mechanisms that may be mediating this effect, we conducted in vitro studies that utilized sera from obese and normal-weight patients with breast cancer. Exposure to sera from obese patients stimulated greater macrophage COX-2 expression and PGE2 production. This was correlated with enhanced preadipocyte aromatase expression following incubation in conditioned media (CM) collected from the obese-patient, sera-exposed macrophages, an effect neutralized by COX-2 inhibition with celecoxib. In addition, CM from macrophage/preadipocyte cocultures exposed to sera from obese patients stimulated greater breast cancer cell ERa activity, proliferation, and migration compared with sera from normal-weight patients, and these differences were eliminated or reduced by the addition of an aromatase inhibitor during CM generation. Prospective studies designed to examine the clinical benefit of NSAID use in obese patients with breast cancer are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84905982814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905982814&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-3603

DO - 10.1158/0008-5472.CAN-13-3603

M3 - Article

C2 - 25125682

AN - SCOPUS:84905982814

VL - 74

SP - 4446

EP - 4457

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 16

ER -